ArticleMedical oncology (Northwood, London, England)2015
Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Resection of sphenoid wing meningioma with blood pressure augmentation reverses acute symptomatic left middle cerebral artery syndrome: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- PGAM1: a potential therapeutic target mediating Wnt/β-catenin signaling drives breast cancer progression.Discover oncology · 2025Article
- Downregulation of lncRNA-MALAT1, Altered Immunohistochemical Expression of Cyclin D1 Protein and E-Cadherin Protein in Correlation to Meningioma Grades.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.Molecular therapy. Oncology · 2024Review
- RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation.Cancers · 2024Article
- Epigenetic Downregulation of Hsa-miR-193b-3p Increases Cyclin D1 Expression Level and Cell Proliferation in Human Meningiomas.International journal of molecular sciences · 2023Article
- Expression of Cell-Cycle Regulatory Proteins pRb, Cyclin D1, and p53 Is Not Associated with Recurrence Rates of Equine Sarcoids.Veterinary sciences · 2022Article
- CDK 4/6 inhibitors for the treatment of meningioma.Frontiers in oncology · 2022Review
- GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma.EBioMedicine · 2020Article
- DNA repair and cell synthesis proteins: immunohistochemical expression and correlation with recurrence-regrowth in meningiomas.Journal of molecular histology · 2020Article
- XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.International journal of molecular medicine · 2020Article
- Molecular Mechanism and Approach in Progression of Meningioma.Frontiers in oncology · 2020Review
- Meningioma Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.Journal of neuro-oncology · 2019Article
- Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulation.Oncology letters · 2019Article
- Tea Polysaccharide Prevents Colitis-Associated Carcinogenesis in Mice by Inhibiting the Proliferation and Invasion of Tumor Cells.International journal of molecular sciences · 2018Article
- HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer.Virchows Archiv : an international journal of pathology · 2017Article
- Article
- Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.OncoTargets and therapy · 2017Article
- Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin D1 has been reported overexpressed in many malignant cancers. However, the expression pattern and biological function of cyclin D1 in meningiomas are still unknown. In this study, we examined the expression of cyclin D1 in meningioma with immunohistochemistry and correlated the measure to the recurrence. Potential effects of cyclin D1 on tumor growth and apoptosis were also examined in representative cell lines (IOMM-Lee and CH157) by inhibiting cyclin D1 with RNA interference. We demonstrate that cyclin D1 mRNA and protein expression are positively correlated with meningioma grade and that higher cyclin D1 expression correlates with higher recurrence. Knockdown of cyclin D1 by the siRNA decreased IOMM-Lee and CH157 cell proliferation, promoted the rate of apoptosis and attenuated invasive capacity. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot analysis revealed that cells stably underexpressing cyclin D1 showed lower expression of survivin and the antiapoptotic protein B cell lymphoma-2 (Bcl-2) compared to control cells. These results indicate that high cyclin D1 expression is associated with a poor outcome of meningioma patients and knockdown of cyclin D1 expression may be a potential treatment for malignant meningioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.